This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions containing such molecules, and processes of using such pesticidal compositions against such pests. These pesticidal compositions may be used, for example, as acaricides, insecticides, miticides, molluscicides, and nematicides. This document discloses molecules having the following formula (“Formula One”). ##STR00001##

This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions containing such molecules, and processes of using such pesticidal compositions against such pests. These pesticidal compositions may be used, for example, as acaricides, insecticides, miticides, molluscicides, and nematicides. This document discloses molecules having the following formula (“Formula One”). ##STR00001##

The present application discloses compositions and methods of synthesis and use of .sup.18F- or .sup.19F-labeled molecules of use in PET, SPECT and/or MR imaging. Preferably, the .sup.18F or .sup.19F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex to a bifunctional chelating agent, which may then be directly or indirectly attached to the targeting molecule. In other embodiments, the .sup.18F or .sup.19F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. The disclosed methods and compositions allow the simple and reproducible labeling of molecules at very high efficiency and specific activity in 30 minutes or less. In preferred embodiments, the bifunctional chelating agent bound to .sup.18F- or .sup.19F-metal complex may be conjugated to the molecule to be labeled at a reduced temperature, e.g. room temperature.

The present application discloses compositions and methods of synthesis and use of .sup.18F- or .sup.19F-labeled molecules of use in PET, SPECT and/or MR imaging. Preferably, the .sup.18F or .sup.19F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex to a bifunctional chelating agent, which may then be directly or indirectly attached to the targeting molecule. In other embodiments, the .sup.18F or .sup.19F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. The disclosed methods and compositions allow the simple and reproducible labeling of molecules at very high efficiency and specific activity in 30 minutes or less. In preferred embodiments, the bifunctional chelating agent bound to .sup.18F- or .sup.19F-metal complex may be conjugated to the molecule to be labeled at a reduced temperature, e.g. room temperature.

The present description relates to a method for binding to a target molecule having an aldehyde compound derived from N-(2-aminoethyl)pyrrole, which compound also has a moiety of interest, to compounds (conjugates) obtained by this method, having both the target molecule and the moiety of interest and to novel substances derived from N-(2-aminoethyl)pyrrole. In one embodiment, the compound has the formula of Formula II ##STR00001##
wherein R1, R2 and R3 independently are H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein R4, R5, R6, R7 and R8 independently are H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or -LM, wherein L is absent or is a linker and M is a moiety of interest selected from a nucleotide, an oligonucleotide, a peptide, a label, a cytotoxic agent, a partner of a binding pair and a functional group, wherein two of R4, R5, R6, R7, and R8 optionally are linked to form a substituted or unsubstituted cycloalkyl or a substituted or unsubstituted heterocycloalkyl, and T is a target molecule selected from the group consisting of a solid phase, a polypeptide, a protein, a carbohydrate, a nucleotide and a nucleic acid, with the proviso that at least one of R4, R5, R6, R7 or R8 is -LM.

There is provided a non-aqueous electrolyte solution enabling fabrication of a non-aqueous electrolyte solution secondary battery which achieves suppressed gas generation when used under high temperature environment and the improved residual capacity of the battery, and the improved cycle characteristic thereof, and further, is excellent in discharge load characteristic (dischargeable at high rate), and a non-aqueous electrolyte solution secondary battery using the non-aqueous electrolyte solution. There is provided a non-aqueous electrolyte solution used in a non-aqueous electrolyte solution secondary battery including a positive electrode having a positive electrode active material capable of absorbing and releasing a metal ion and a negative electrode having a negative electrode active material capable of absorbing and releasing a metal ion, which solution contains a bismaleimide compound having a specific structure, and a non-aqueous electrolyte solution secondary battery using the solution.

There is provided a non-aqueous electrolyte solution enabling fabrication of a non-aqueous electrolyte solution secondary battery which achieves suppressed gas generation when used under high temperature environment and the improved residual capacity of the battery, and the improved cycle characteristic thereof, and further, is excellent in discharge load characteristic (dischargeable at high rate), and a non-aqueous electrolyte solution secondary battery using the non-aqueous electrolyte solution. There is provided a non-aqueous electrolyte solution used in a non-aqueous electrolyte solution secondary battery including a positive electrode having a positive electrode active material capable of absorbing and releasing a metal ion and a negative electrode having a negative electrode active material capable of absorbing and releasing a metal ion, which solution contains a bismaleimide compound having a specific structure, and a non-aqueous electrolyte solution secondary battery using the solution.

Provided are a polymerizable compound having at least one monovalent group (A), a polymerizable composition containing the polymerizable compound, a liquid crystal composite prepared from the polymerizable composition, and a liquid crystal device having the polymerizable composition. ##STR00001## In monovalent group (A), R.sup.1 and R.sup.2 are independently hydrogen, halogen or alkyl having 1 to 20 carbons, and in the alkyl, at least one piece of —CH.sub.2— may be replaced by —O— or —S—, and at least one piece of —(CH.sub.2).sub.2— may be replaced by —CH═CH—, and in the groups, at least one hydrogen may be replaced by halogen.

Provided are a polymerizable compound having at least one monovalent group (A), a polymerizable composition containing the polymerizable compound, a liquid crystal composite prepared from the polymerizable composition, and a liquid crystal device having the polymerizable composition. ##STR00001## In monovalent group (A), R.sup.1 and R.sup.2 are independently hydrogen, halogen or alkyl having 1 to 20 carbons, and in the alkyl, at least one piece of —CH.sub.2— may be replaced by —O— or —S—, and at least one piece of —(CH.sub.2).sub.2— may be replaced by —CH═CH—, and in the groups, at least one hydrogen may be replaced by halogen.

The present invention provides modified cycloalkyne compounds; and method of use of such compounds in modifying biomolecules. The present invention features a cycloaddition reaction that can be carried out under physiological conditions. In general, the invention involves reacting a modified cycloalkyne with an azide moiety on a target biomolecule, generating a covalently modified biomolecule. The selectivity of the reaction and its compatibility with aqueous environments provide for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).